Replies to post #178 on Immatics NV (IMTX)

[FACT-MASTER]

Well thank you for sharing that interesting article. I note that it references IMA402 which is Immatics proprietary targeting prame.

https://www.boerse-online.de/nachrichten/aktien/geheimtipp-diese-voellig-unbekannte-biotech-aktie-aus-deutschland-hat-niemand-auf-dem-schirm-20352622.html

Insider tip? Nobody has this completely unknown biotech stock from Germany on their radar

Along with BioNTech and other pharmaceutical companies, the shares of this German company are a hot candidate for a big price jump in 2024.

More than just BioNTech. Anyone looking for German biotech stocks will quickly end up with the Mainz stocks. There are other promising stocks that speculative investors should at least keep an eye on. For example, there is Immatics from Tübingen. The company focuses on the development and production of T cell-based immunotherapies for the treatment of cancer. What sounds complicated is essentially aimed at modifying T cells and then developing an immunotherapy that selectively and effectively attacks a patient's tumors.

The research on this takes place at three locations: Tübingen, Texas and Munich. The group also works with some well-known biotech giants such as Bristol-Myers-Squibb, Genmab and Moderna, who actively promote research. With more than 500 million US dollars, Immatics has enough financial resources to carry out clinical studies on the various active ingredients. 2024 could be a particularly exciting year for investors.

Will 2024 boost Immatics shares?
“We are working intensively to make IMA402 available to a broad patient population as quickly as possible and look forward to publishing the first clinical data in 2024,” the company announced last year. And the active ingredient for the treatment of cancer called IMA402 is not the only drug about which there could be news this year. There will also be new data for the active ingredient IMA-203 this year. In total, the Germans are currently preparing eleven treatments or are already in the first clinical study phases.

The year could have some surprises in store for the stock. The fact that the stock reacts to even small results was shown last year when the price shot up by 30 percent in one day after the publication of some clinical data.

That's what the analysts say
The stock is currently not receiving much attention from analysts on Wall Street. A current analysis by Mizuho Securities still believes the stock will have a medium-term price increase of over 13 percent. Two other analyzes at the end of last year were significantly higher. Leerink Partners even believed the stock had 86.69 upside potential and Chardan Capital had an incredible 103 percent.

According to data from the MarketScreener platform, six analysts currently recommend buying the stock. The average price potential is almost 60 percent. Risk-taking investors should therefore not lose sight of the stock this year.

[FACT-MASTER]

Noticed IMA402 was mentioned in the Q1 report and was initially focused on melanoma (similar to IMA203) Not sure when results will be coming out on IMA402, however from the article you posted, this trial could be well advanced. The announcement regarding the Oral Presentation at the Society for Melanoma Research Congress 2024 - October 11/24 only mentions IMA203. (https://finance.yahoo.com/news/immatics-announces-upcoming-oral-presentation-110000681.html)

I'll whisper this: Given that IMA203 received RMAT designation almost a year ago, i speculate that it is a distince possibility that FDA approval will be announced for IMA203 in and around the Melanoma Research Congress October 10-13/24 in New Orleans, Louisiana - just my opinion.



https://finance.yahoo.com/news/immatics-announces-first-quarter-2024-110000778.html

TCER® IMA402 (PRAME)

Immatics initiated the Phase 1/2 trial investigating the company’s fully owned TCER® candidate IMA402 in patients with recurrent and/or refractory solid tumors in August 2023 and the first patients have been dosed. Initial focus indications are ovarian cancer, lung cancer, uterine cancer and cutaneous and uveal melanoma, among others. IMA402 targets an HLA-A*02:01-presented peptide derived from the tumor antigen PRAME. This target peptide has been selected based on natural expression in native solid primary tumors and metastases at particularly high target density (peptide copy number per tumor cell identified by Immatics’ proprietary quantitative mass spectrometry engine XPRESIDENT®).

Immatics has recently engaged Patheon UK Limited, a subsidiary of ThermoFisher Scientific Inc., for the manufacturing of clinical IMA402 batches for its use within a potential registration-enabling trial. Patient recruitment and dose escalation continue to scale. First clinical data in at least 15 patients in dose escalation across multiple solid cancers, but initially focused on melanoma, is anticipated to be announced in 2H 2024.

[FACT-MASTER]

I'll add this analysis to the article:

1. Institutional ownership at June 30/24 = 75%
https://www.nasdaq.com/market-activity/stocks/imtx/institutional-holdings

2. Short position at 08/30/2024 = 10,415,614\
https://www.nasdaq.com/market-activity/stocks/imtx/short-interest

Could the upcoming data release at the upcoming ESMO (tomorrow) and Society for Melanoma Research Congress (Oct.11/24) cause a short squeeze?
The above evidence demonstrates that in this instance, it could be a real possibility, imo.

Let's keep in touch.
FM